
Fidelis Care is owned by Centene Corporation (NYSE: CNC), which completed its $3.75 billion acquisition of the health plan on July 2, 2018. Founded in 1993 by the Catholic bishops of New York State as a nonprofit, mission-driven insurer, Fidelis Care is now Centene's health plan in New York and serves more than 2.4 million members statewide through Medicaid managed care, Child Health Plus, the Essential Plan, Medicare Advantage, and NY State of Health marketplace coverage.
Parent Company
Acquired
2018
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Fidelis Care | Centene Corporation | Wholly owned |
Fidelis Care was founded in 1993 by the Catholic bishops of New York State as the New York State Catholic Health Plan, a nonprofit organization created to extend health coverage to low-income and uninsured New Yorkers. It entered Medicaid managed care, Child Health Plus, and later Family Health Plus, growing steadily through the 1990s and 2000s on a mission mandate that prioritized underserved communities.
The plan adopted the Fidelis Care name as it expanded statewide, opening community offices and building one of the deepest enrollment footprints in New York. Under CEO Rev. Patrick Frawley, Fidelis grew to more than 1.6 million members by mid-2017, generating $4.8 billion in revenue in the first half of that year alone.
Centene announced the $3.75 billion acquisition on September 12, 2017, and closed July 2, 2018. Under Centene, membership grew to more than 2.4 million by 2025, making Fidelis the largest mainstream Medicaid managed care plan in New York City (570,000-plus NYC Medicaid members per October 2025 state enrollment data) and a statewide leader. Fidelis added Essential Plan, Medicare Advantage Dual Advantage, and NY State of Health marketplace products, with its exchange business covering approximately 118,000 members as of 2025.
Is Centene a subsidiary of another company?
No, Centene Corporation is an independent, publicly traded corporation with no parent company. The company operates independently with its own management structure and board of directors, though it has grown through numerous acquisitions throughout its history, including the transformative $17.3 billion acquisition of WellCare Health Plans in January 2020.
Is Centene publicly traded?
Yes, Centene Corporation is publicly traded on the New York Stock Exchange under the ticker symbol CNC. The company has been publicly traded since its IPO in 2001, when it had three health plans, $327 million in revenue, and 235,000 members. As of 2025, the company is ranked No. 23 on the Fortune 500 list.
When was Centene founded?
Centene traces its origins to 1984 when Elizabeth Brinn founded Managed Health Services as a non profit organization in Milwaukee, Wisconsin. The company was renamed Centene Corporation in 1997 when Michael Neidorff was named President and CEO, and the corporate office was established in St. Louis, Missouri. The company went public in 2001.
Who founded Centene?
Centene was founded by Elizabeth Brinn in 1984 as Managed Health Services, a non profit organization focused on providing healthcare services to Medicaid populations in Milwaukee, Wisconsin. After her death, the organization was converted to a for profit company. Michael Neidorff was named CEO in 1997 and grew Centene from a local health plan to a national healthcare leader over 25 years.
What is Centene's annual revenue?
For fiscal year 2025 (ended December 31, 2025), Centene reported total revenue of $194.8 billion, a 19% increase from $163.1 billion in FY2024. Premium and service revenues were $174.6 billion, up 20% year over year. The company recorded a GAAP net loss of $6.7 billion, primarily due to a $6.7 billion non cash goodwill impairment charge. Adjusted diluted EPS was $2.08, down from $7.17 in FY2024.
What is Centene's market position?
Centene is the largest Medicaid managed care organization in the United States, the longest running carrier in the Health Insurance Marketplace, and a national leader in Medicare Prescription Drug Plans. The company serves 27.6 million members across all 50 states as of December 31, 2025, with revenue from Medicaid (57%), Commercial (21%), Medicare (19%), and Other (3%) segments. Centene is ranked No. 23 on the Fortune 500 and No. 42 on the Fortune Global 500.
Who is Centene's CEO?
Sarah M. London has served as Chief Executive Officer of Centene Corporation since 2022. She is the first woman to lead the company. Under her leadership, Centene has refocused on three core lines of business: Medicaid, Medicare, and the Health Insurance Marketplace. In 2025, London navigated the company through significant challenges including the $6.7 billion goodwill impairment, Marketplace risk adjustment shortfall, and elevated Medicaid medical cost trends.
What is the WellCare acquisition?
In January 2020, Centene completed the acquisition of WellCare Health Plans in a $17.3 billion transaction (enterprise value). WellCare shareholders received 3.38 shares of Centene common stock and $120 in cash for each share of WellCare common stock. The acquisition made Centene a nationwide company serving all 50 states with approximately 24 million members, expanded its Medicare platform, and extended its Medicaid offerings. WellCare became a wholly owned subsidiary of Centene and continues to operate as a brand under the Centene umbrella.
Fidelis Care retains a community-health mission inherited from its nonprofit founders. It funds community grants in New York through the foundation created from the sale proceeds, operates multilingual member services and community offices, and runs health education, preventive screening, and food security programs in low-income neighborhoods.
The plan participates in New York's Health Equity programs and CalAIM-style social care initiatives, holds NCQA accreditation, and is subject to New York State quality incentive programs that score plans on clinical outcomes and member experience.
Fidelis Care has received NCQA accreditation for its Medicaid and marketplace plans and New York State quality awards for member satisfaction and clinical measures. Its community benefit programs have been recognized by New York public health organizations, and the plan's Essential Plan is among the most-enrolled in the state.
Nonprofit Sale Controversy: Centene's 2017 to 2018 acquisition of the nonprofit Fidelis Care drew criticism from some New York legislators and health advocates who questioned whether charitable assets built under nonprofit status should convert into for-profit value, and how sale proceeds would be used. The deal was ultimately approved with proceeds directed to a new charitable foundation.
Rate-Filing Scrutiny: Like other New York insurers, Fidelis files annual premium increases with the Department of Financial Services, drawing periodic advocacy-group scrutiny. Its 2025 individual-market filing affected approximately 118,000 members.
Medicaid Oversight: New York regulators periodically audit Medicaid managed care plans on timely access, network adequacy, and encounter data; Fidelis has received standard corrective action requests in line with industry-wide findings.
Centene Multistate Settlement: Parent Centene's $1 billion-plus pharmacy benefit manager settlements with states beginning in 2021 included scrutiny of subsidiary practices, though the core conduct predated Fidelis's ownership period.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Centene | USA | 1977 | Mass market | United states | All-ages | |
| Humana | USA | 1990 | Growth segment | United states | All-ages | |
| Humana | USA | 1985 | Market leader | United states | Seniors-65-plus | |
| Elevance Health | USA | 2024 | Mass market | United states | All-ages | |
| Centene | USA | 2014 | Market leader | United states | All-ages | |
| Centene | USA | 1985 | Mass market | United states | All-ages |
Healthcare PharmaceuticalsOwned by Centene Corporation
Centene Corporation's California health plan brand, founded in 1977 and acquired for approximately $6.8 billion in 2016, serving about three million members through Medi-Cal, Medicare, marketplace, and commercial plans.
Healthcare PharmaceuticalsOwned by Humana Inc.
Humana's Medicaid managed care product line operating as Humana Healthy Horizons across 13 states, with Georgia and Texas launches planned and D-SNP growth of 18 percent in 2026.
Healthcare PharmaceuticalsOwned by Humana Inc.
Humana's Medicare product line, the second-largest Medicare Advantage insurer in the United States, which grew membership about 20 percent in the 2026 annual enrollment period.
Healthcare PharmaceuticalsOwned by Elevance Health Inc.
Elevance Health's government health plan brand for Medicaid, CHIP, and Medicare in states where Anthem Blue Cross Blue Shield does not operate, rebranded from Amerigroup in January 2024.
Healthcare PharmaceuticalsOwned by Centene Corporation
Centene Corporation's Affordable Care Act marketplace health insurance brand, launched in 2014 and serving 5.8 million members across 29 states as the largest individual-market issuer.
Healthcare PharmaceuticalsOwned by Centene Corporation
Centene Corporation's national Medicare Advantage and prescription drug plan brand, acquired from WellCare Health Plans for $17.3 billion in January 2020.
Market Positioning: Fidelis Care competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Centene Corporation, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
Duane Reade is privately owned, unlike Fidelis Care which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
Amgen operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
Boots is privately owned, unlike Fidelis Care which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Novo Nordisk
Danish pharmaceutical company specializing in diabetes care and obesity treatment. Founded in 1923, headquartered in Bagsvaerd, Denmark. World leader in diabetes care and a leader in obesity treatment with Ozempic, Wegovy, and the investigational CagriSema. CEO Lars Fruergaard Jorgensen departed in March 2025; interim leadership under board chairman Helge Lund until a permanent CEO is appointed.
Novo Nordisk operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
Pharmacy Direct is privately owned, unlike Fidelis Care which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
Retavase is privately owned, unlike Fidelis Care which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.